HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VS 215

structure given in first source

Also Known As:

4-(tert-butoxycarbonylamino)-3-hydroxy-5-phenyl-2-pentafluorophenyl-2-pentenenitrile; VS-215

Networked: 41 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Nitriles: 227
  - VS 215: 41

Experts

1.	Anderl-Straub, Sarah: 1 article (04/2022)
2.	Baldeiras, Inês: 1 article (04/2022)
3.	Diehl-Schmid, Janine: 1 article (04/2022)
4.	Grimmer, Timo: 1 article (04/2022)
5.	Halbgebauer, Steffen: 1 article (04/2022)
6.	Kort, Anna M: 1 article (04/2022)
7.	Lima, Marisa: 1 article (04/2022)
8.	Ludolph, Albert C: 1 article (04/2022)
9.	Marques, Tainá M: 1 article (04/2022)
10.	Oeckl, Patrick: 1 article (04/2022)

Related Diseases

1.	Hemorrhage 12/01/2017 - " time (43.2 ± 21.8 vs 230.6 ± 87.1 minutes) was significantly longer and bleeding volume (5.3 ± 3.1 vs 215.0 ± 170.2 mL) significantly greater in the PSF+VP group. " 08/01/2017 - "No significant difference was observed in incidence of advanced stage III or IV disease between the 2 groups (P=0.56 and 0.51, respectively), whereas a longer operation time (287 [95 to 700] vs. 215 [60 to 900] min, respectively; P<0.001) and greater amount of intraoperative bleeding (595 [15 to 4530] vs. 235 [1 to 11565] mL, respectively; P<0.001) were observed in the IMA-ligated group. " 09/01/2015 - "No difference was found in intraoperative bleeding between the antithrombotic agent group and the control group (mean 255 ml vs 215 ml, Mann-Whitney U-test, p = 0.547), and no patient required transfusion. "
2.	Amenorrhea 12/01/2016 - "At 1-month post-NovaSure treatment, a significant reduction of mean PBLAC scores was observed in cirrhotic patients compared to those at baseline (0.4 ± 1.3 vs 215.2 ± 410.9, P < 0.001), and the amenorrhea rate was 88.5%. "
3.	Acidosis 02/28/2022 - "Acidosis also decreased plasma PTH in all groups, 96.5 ± 22.3 vs. 107.3 ± 19.1 pg/mL, 113.1 ± 17.3 vs. 185.8 ± 22.2 pg/mL and 504.9 ± 75.7 vs. 1255.4 ± 181.1 pg/mL. FGF23 showed a strong positive correlation with PTH (r = 0.877, p < 0.0001) and further studies demonstrated that acidosis did not influence plasma FGF23 concentrations in parathyroidectomized rats, 190.0 ± 31.6 vs. 215 ± 25.6 pg/mL. In conclusion, plasma concentrations of FGF23 are consistently decreased in rats with metabolic acidosis secondary to increased acid intake, both in animals with intact renal function and with decreased renal function. "
4.	Neoplasms (Cancer) 07/20/2021 - "The mean tumor CD63 and CD9 scores in pre-NCCR biopsy vs. post-NCCR resected rectum were 106 vs. 165 (P = 0.0022) and 136 vs. 215 (P < 0.0001) respectively. " 10/01/2020 - "Patients with cancer were significantly less likely to receive POLST-discordant care than those without cancer (comfort only: 41/181 [23%] vs 80/220 [36%], aRR, 0.60 [95% CI, 0.43-0.85]; limited interventions: 100/321 [31%] vs 215/440 [49%], aRR, 0.63 [95% CI, 0.51-0.78]). " 05/05/2021 - "However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). " 03/01/2013 - "Comparing between noncomplex and complex tumors, statistical differences were found in operative time (181 min vs 215 min, P=0.028) and ischemia time (21 min vs 24 min, P=0.006). "
5.	Pain (Aches) 03/01/2002 - "Recurrence and persisting pain were less after mesh repair (overall recurrences: 88 in 4,426 vs. 187 in 3,795; OR 0.43, 95% CI 0.34-0.55; P <.001) (overall persistent pain: 120 in 2,368 vs. 215 in 1,998; OR 0.36, 95% CI 0.29-0.46; P <.001), regardless of the non-mesh comparator. " 06/01/2011 - "Subjects walked 18% longer before the onset of claudication pain (183 ± 84 s vs. 215 ± 99 s; P ≤ 0.01) and had a 17% longer peak walking time (467 ± 223 s vs. 533 ± 233 s; P ≤ 0.05) following BR vs. PL. " 01/01/2022 - "Reactogenicity events were more common in the co-administration group than in the NVX-CoV2373 alone group: tenderness (113 [64·9%] of 174 vs 592 [53·3%] of 1111) or pain (69 [39·7%] vs 325 [29·3%]) at injection site, fatigue (48 [27·7%] vs 215 [19·4%]), and muscle pain (49 [28·3%] vs 237 [21·4%]). "

Related Drugs and Biologics

1.	Acids
2.	Glucose (Dextrose)
3.	Interleukin-6 (Interleukin 6)
4.	Aspirin (Acetylsalicylic Acid)
5.	Lactic Acid (Lactate)
6.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
7.	Salts
8.	Messenger RNA (mRNA)
9.	Prostaglandins F
10.	Norepinephrine (Noradrenaline)

Related Therapies and Procedures

1.	Length of Stay
2.	Operative Time
3.	Esophagectomy